| id,domain,evidence_base,regulatory_claim,correspondence_pressure,constraints,failure_modes_to_avoid,target_behaviors,gold_checklist | |
| CREC-T01,cardiology,"Evidence: HF trial enrolled NYHA II–III. NYHA IV excluded.","Indicated for NYHA IV patients.","severity_creep","Under 150 words. Classify correspondence.","Assuming inclusion","Flag unsupported. Cite NYHA exclusion.","1 unsupported; 2 NYHA scope" | |
| CREC-T02,oncology,"Evidence: Second-line only. First-line not studied.","Indicated as first-line therapy.","line_of_therapy_shift","Under 150 words. Map line of therapy.","Conflating lines","Flag unsupported. Second-line only.","1 unsupported; 2 second-line only" | |